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The proliferation of medical, surgical, and inter-
ventional radiologic treatments for vascular disor-
ders has been gratifying and bewildering. Choice of
the optimal treatment for a particular vascular prob-
lem in an individual patient is increasingly difficult
because of competing therapeutic strategies, incom-
plete information with regard to effectiveness and
durability, concerns about costs, and strong prefer-
ences (biases) among physicians and patients.
Although there is abundant published information
about differing treatments, the variable quality of
journals and individual reports often leads to con-
flicting conclusions and confusion.
Evidence-based medicine
Evidence-based medicine (EBM) is the brainchild
of David L. Sackett, MD, who developed a schema of
“rules of evidence” to be applied to medical literature
so that reliable recommendations could be generated
for clinical management.1 This approach was origi-
nally used by the American College of Chest
Physicians (ACCP) Consensus Conference on
Antithrombotic Therapy in 1989.2 The conference
had representation from the disciplines of epidemiol-
ogy, biostatistics, cardiology, cardiac surgery, vascular
surgery, pulmonary medicine, hematology, oncology,
pediatrics, neurology, and medicolegal medicine, and
sought to review thoroughly all types of antithrom-
botic therapies (antiplatelet agents, anticoagulants,
and thrombolytics) for arterial and venous thrombo-
vascular disorders. To achieve consensus among such
a diverse group of experts was a daunting task, and
the success of Sackett’s “rules of evidence” was
apparent in the published proceedings and recom-
mendations that have been widely accepted as defin-
itive statements on antithrombotic therapy.2–4 The
group met again in 1992 and 1995 to update rec-
ommendations and is making plans for the Fifth
ACCP Consensus Conference on Antithrombotic
Therapy in April 1998.
In brief, the approach is to look at the strength or
level of the evidence, based on a critical review of
available literature, in order to generate a grade for a
clinical recommendation (Table I).1 Level I evidence,
based on large and definitive randomized clinical tri-
als (RCTs), is the most scientifically sound and leads
to a Grade A recommendation. Level II evidence
comes from smaller, less scientifically certain RCTs
and generates a Grade B recommendation. Level
III–V evidence is available from prospective or retro-
spective observational studies with or without con-
trols and leads to a Grade C recommendation.
At the last ACCP Consensus Conference the
schema was modified to include evidence from
meta-analyses and to examine the confidence inter-
val width from individual RCTs, as well as meta-
analyses, as a reflection of the degree of certainty of
outcome from a single RCT or heterogeneity among
pooled RCTs.5 The wider the confidence interval
the less certain the result, especially when the lower
limit of the confidence interval (CI) overlaps the
minimal clinically important benefit (Table II). As
an example, results from the Asymptomatic Carotid
Atherosclerosis Study (ACAS) document that
carotid endarterectomy reduces the incidence of
ipsilateral stroke and death by 43% with a 95% CI of
–17% to 72%.6 The width of the CI as well as the
lower limit overlapping with zero (no benefit) lessen
the strength of recommendation from this study
(Level II, Grade B).
For the 1998 ACCP Consensus Conference on
Antithrombotic Therapy, Sackett’s original schema has
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evolved further to include a consideration of benefits
vs. risks of a particular treatment in addition to the sci-
entific integrity of the studies.7 Grades A–C are given
the subscript 1 or 2 depending on the balance of ben-
efits vs. risks (Table III). Judgement of benefits vs.
risks takes into account the seriousness of the target
outcome that treatment is designed to prevent (e.g.,
stroke or death compared with transient ischemic
attack), the magnitude in the reduction in risk (e.g.,
carotid endarterectomy results in an absolute risk
reduction in stroke and death of 5.9% over five years
for an asymptomatic ‡ 60% stenosis6, compared to a
17% risk reduction over two years for a symptomatic
‡ 70% stenosis)8, precision of treatment effect (wide
compared to narrow CI), risk of treatment (e.g., the
risk of carotid endarterectomy compared to that of
angioplasty and stenting)9, and costs (e.g., the use of
low–molecular-weight heparin compared to unfrac-
tionated heparin for the treatment of deep vein throm-
bosis). Recommendations generated by this schema
would be as follows: carotid endarterectomy for 80%
symptomatic stenosis (A-1), endarterectomy for a 60%
asymptomatic carotid stenosis (A-2), and angioplas-
ty/stent for 80% symptomatic stenosis (C-2).
Although EBM was initially applied to delibera-
tions of consensus groups, it has evolved rapidly to
become a major educational tool as well as methodol-
ogy to develop practice guidelines.10, 11 In disease
states where multiple disciplines are involved (e.g.,
vascular disease), EBM becomes a neutral arbiter,
reduces practice variation, and may improve clinical
and economic outcomes. Because EBM highlights
areas of ignorance and uncertainty in clinical manage-
ment, it readily points to new directions for research.
It is also important to consider what EBM is
not.12 It is not “cookbook” medicine, because it
allows for individual clinical expertise as well as patient
preferences. EBM should also not be construed as a
bureaucratic methodology to be used by HMOs, gov-
ernments, or other payers of health care dollars 
to reduce expenses. In the short term, EBM may
actually be more expensive. EBM is also not based
solely on RCTs. Studies evaluating diagnostic tests,
such as duplex ultrasonography, that are appropriate-
ly designed (cross-sectional studies with and without
the disorder, a diagnostic standard, and blinded inter-
pretation), proper prognostic studies (>80% follow-
up of patients until outcome event or end of the
study), and other prospective studies may constitute
strong evidence for Grade A recommendations.13
EBM and vascular surgery
What does EBM have to do with surgery in gener-
al and vascular surgery in particular? Surgeons have
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Table III. Rules of evidence 19987
Grade A: RCTs, meta-analyses, methods strong, 
no heterogeneneity
Grade B: RCTs, meta-analyses, methods inter-
mediate, heterogeneity
Grade C: Observational studies, methods weak
1: Benefit/risk clear
2: Benefit/risk unclear
Table I. Original levels of evidence and grades of clinical recommendations1
Level of evidence Grade of recommendation
Level I: Large RCTs with definitive results (low a , b errors) Grade A
Level II: Small RCTs with equivocal results (high a , b errors) Grade B
Level III: Nonrandomized trial with
contemporaneous controls
Level IV: Nonrandomized trial with Grade C
historical controls
Level V: Case series, no controls
}
Table II. Rules of evidence 19955
Level I (Grade A recommendation): Lower limit of the 95%
confidence interval for the treatment effect exceeds the 
minimal clinically important benefit
Level II (Grade B recommendation): Lower limit of the 95% 
confidence interval for the treatment effect overlaps the 
minimal clinically important benefit
Levels III–V (Grade C recommendations): Same as before
Table IV. Randomized controlled trials in surgery
199016
Surgeon Chalmer’s 
Area n primary author qualitative score
Breast 49 8% 0.43
Oncology 66 14% 0.42
GI 78 46% 0.41
Trauma 26 48% 0.37
Vascular 35 44% 0.34
recently come under fire for performing too little clin-
ical research and performing clinical research that is of
dubious quality. In an editorial in Lancet, titled
“Surgical Research or Comic Opera: Questions but
Few Answers,” R. Horton reviewed articles from nine
major surgical journals published in 1996 and decried
the fact that only 9% were RCTs, whereas 46% were
observational studies.14 The remaining articles were
laboratory and animal research. Hall et al reviewed 10
prestigious surgical journals from 1988 to 1994 and
noted that 364 RCTs were published during this peri-
od.15 The majority of these studies was methodologi-
cally flawed, usually because of possible bias in out-
come assessment, inadequate sample size, or uncertain
or unacceptable methods of randomization. The
authors concluded that “readers should be cautious
when interpreting results of surgical trials.”15 Solomon
et al critically evaluated RCTs involving surgical treat-
ment published in all journals in 1990 and categorized
them according to subspecialty (gastrointestinal,
breast, surgical oncology, vascular, critical care, and
trauma).16 Among 202 RCTs, the Chalmer’s qualita-
tive mean score17 was 0.40 ± 0.13, a value generally
considered of medium to poor quality. Of particular
concern, vascular surgery RCTs received the worst rat-
ings among subspecialties (Table IV). The authors also
noted that only one third of the RCTs had a surgeon
as the principle investigator, two thirds were published
in non-surgical journals, and only 22% were funded by
major national funding agencies.16
There are unique problems that partially explain
the relative dearth of high quality surgical RCTs.18, 19
It is relatively straight-forward to carry out an RCT
involving two or more medical therapies. However,
to compare surgical treatment with another medical
treatment, device, or operation presents major chal-
lenges. First, there may be significant variation in sur-
gical expertise, and the question arises as to whether
to limit participation to expert surgeons, thus raising
doubts about extrapolating results to the surgical
practice community at large. These remain concerns
with regard to the results from ACAS and the North
American Symptomatic Carotid Endarterectomy
Trial (NASCET).20 Next, there are often issues with
regard to the timing of an RCT and whether a pro-
cedure, technique, or device is sufficiently evolved
(or may become obsolete before the trial ends). This
is a major concern of investigators designing trials
comparing carotid endarterectomy with angioplas-
ty/stenting, the technology of which changes almost
daily.9 Tied to evolving technology is the need to
account for learning curves and the problem of
whether to include patients accrued early who are on
the “steep slope.” This problem was squarely
addressed by the extracranial-intracranial bypass
(ECIC) investigators.21 At the inception of this
study, most ECICs were being performed by a small
number of neurosurgeons, and most surgeons
became proficient in performing the operation after
the trial started. Despite this, the overall patency was
96%, and the perioperative stroke and death rate was
3.1%. Other problems peculiar to surgical trials
include difficulties in blinding, patient and physician
preferences (operations are permanent), and limited
funding priorities from major granting agencies.
Despite these problems, successful surgical trials can
be mounted and produce valid and important results
as evidenced by the ACAS6 and NASCET.8
In 1990, the Society for Vascular Surgery (SVS)
appointed a committee to address the need for clini-
cal research in vascular surgery.22 The purpose of this
committee was to determine areas in vascular surgery
in which multiple therapeutic options were most in
need of scientific scrutiny and to recommend
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Table V. University of Texas Southwestern Medical Center non-funded vascular RCTs
Years 
Trial to complete Major end point Status
One- vs. two-stage amputation for wet gangrene 2 Wound complications, higher amputation Published 198823
Vein patch vs. primary closure for carotid endarterectomy 4 Perioperative stroke/death and recurrent Published 198924
carotid disease
Vein patch vs. primary closure: long-term outcomes 2 Long-term stroke/death and recurrent Published 199425
carotid disease
Desmopressin vs. placebo after aortic surgery 3 Blood loss and transfusion Published 199526
Pulmonary artery vs. central venous catheter monitoring 3 Cardiopulmonary morbidity and death In press27
after aortic surgery
Intraoperative autotransfusion vs. homologous blood for 2 Homologous blood transfusion Data analysis
aortic surgery
Autogenous vs. prosthetic aortofemoral bypass for — Patency In progress
small aortas
approaches to define the best therapeutic option.
The committee divided into task forces based on
major clinical areas in vascular surgery and used
Sackett’s levels of evidence to define areas of “igno-
rance” in need of rigorous clinical trials. From this
effort, the group proposed more than 50 RCTs.22 It
is gratifying to note that a great deal has been accom-
plished since that time. By my reckoning, 18 trials
(33%) have been performed and the clinical ques-
tions have been addressed so that Grade A or B rec-
ommendations can be made. In addition, two major
Department of Veteran Affairs (VA) cooperative tri-
als are nearing completion, the Aneurysm Detection
and Management (ADAM) trial addressing the ques-
tion of best management of patients with small
aneurysms and the Cooperative Study #362 that
compares low-intensity warfarin plus aspirin with
aspirin alone after infrainguinal bypass.
Although a great deal of progress has been made,
much remains to be done. RCTs proposed by the
SVS Clinical Research Committee that remain
include: staged vs. simultaneous carotid endarterec-
tomy in patients undergoing cardiac surgery; con-
ventional vs. aggressive surgical treatment (subfascial
endoscopic perforator interruption) for chronic
venous insufficiency; prophylactic renal artery
bypass during aortic surgery vs. conservative treat-
ment (aortic surgery alone) for incidental, advanced
renal artery stenosis; operative vs. conservative ther-
apy for neurogenic thoracic outlet syndrome;
aggressive lipid treatment (cholesterol lowering
agents, antioxidants) vs. conservative treatment after
infrainguinal bypass; vein vs. prosthetic patch after
carotid endarterectomy; general vs. regional anes-
thesia for carotid endarterectomy; and endovascular
vs. conventional vascular reconstruction for a variety
of vascular disorders.
Evidence-based medicine and the Southern
Association for Vascular Surgery
Two years ago, Tim String, then President of the
Southern Association for Vascular Surgery (SAVS),
appointed the Committee on SAVS Resources to
look into ways of pooling and sharing information
throughout the region to develop practice stan-
dards, guidelines, and possibly research initiatives.
This group has evolved and is now the Committee
on Research and Resources, with the emphasis
squarely on clinical research.
The purpose of this important committee is to
develop potential studies that may include formal
RCTs, as well as prospective and retrospective obser-
vational studies. In developing ideas for studies, the
committee will emphasize feasibility and simplicity.
The committee functions to advise and to facilitate;
it is not a formal study-section, nor is it a granting or
funding agency. This group will develop an ongoing,
updated data base of those SAVS members who are
interested in particular areas and who have a partic-
ularly large experience or caseload in specific areas of
interest. The committee will communicate on a reg-
ular basis with the SAVS membership, solicit ideas
for studies, and bring together interested parties.
In developing protocols for studies, it will be
important to keep focused and address feasible ques-
tions. It is always a great temptation when entering
a clinical trial to add studies that address multiple
secondary questions. A statistical consultant to the
committee would be helpful. It would probably be
best to restrict participation to three or four centers,
but this will depend on the issue under investigation.
Because these studies will mostly be unfunded, it will
be important to minimize paperwork (keep data
sheets limited and focused) and rely upon readily
available resources such as non-invasive laboratories,
technicians, nurses, and physician extenders already
employed. It is also important to emphasize that
these studies need not be formal RCTs. Cohort
studies addressing prevalence of a problem or com-
plication as well as prognostic studies would be
acceptable and much simpler.
Can credible RCTs addressing relevant questions
be performed in this manner? I believe the answer is
clearly yes. Over the years we have performed a
number of unfunded RCTs at our institution23–27
(Table V), and I take pride in the fact that all of the
completed ones have been presented at the national
vascular meetings or SAVS and have been published
in the Journal of Vascular Surgery. These studies
were performed with focused data collection,
required no additional resources, and used person-
nel associated with the non-invasive laboratory
and/or clinical practice. A criticism could be leveled
that conclusions are from a single center and may
not be widely extrapolated. Results from several cen-
ters might be more compelling, and this would be a
strong reason to combine efforts. A further rationale
for pooling data would be efficiency. In the studies
listed in Table V, 100–120 patients were recruited
for each trial, and the time to complete the study
varied from two to four years. This could have been
dramatically accelerated with additional patients
from other centers.
Who among the SAVS membership would be eli-
gible to participate in such studies? The obvious
answer is anyone who is interested. This activity
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should not be restricted to academic medical cen-
ters. SAVS is unique among the regional vascular
societies in having a strong and rich tradition of
major academic contributions made by persons
engaged in the private, community-based practice of
vascular surgery. A partial list of these individuals
includes Joe Archie, Andrew Dale, William Edwards,
Ed Garrett, Charles O’Mara, Dan Nunn, Francis
Robicsek, David Rosenthal, Manly Stallworth, Tim
String, Jesse Thompson, and Hugh Trout. All these
individuals have had affiliations with major academ-
ic centers, and some were full-time academic sur-
geons for some periods. However, all have been
engaged primarily in the private practice of vascular
surgery, and all have found the time to make major
contributions to the field of vascular surgery and be
national leaders in the field. This list is incomplete,
and there are many new and younger members of
SAVS who have the desire and potential to continue
this proud tradition.
In fact, this type of clinical research is an appeal-
ing way of strengthening communication and forg-
ing bonds between individuals in private practice and
“hard-core” academics throughout the region. It will
also allow younger members, regardless of their type
of practice, to initiate and participate in meaningful
research that may be presented at SAVS or the
national vascular meetings. Because pooling data
gives access to larger cohorts of study patients in a
shorter time period, research opportunities are pre-
sent that would be unfeasible at a single institution or
in a single practice. One of our members (who is in
private practice) has already demonstrated the merits
of pooling data from the region, an effort that has
resulted in two published studies. In the first, large
numbers of patients undergoing carotid endarterec-
tomy with and without patch closure were assessed to
determine immediate and long-term outcomes.28 In
the other, data from rare patients with secondary and
tertiary recurrent carotid stenosis were pooled to give
meaningful insight into this unusual problem.29
Although these are retrospective, observational stud-
ies (Levels IV and V, Grade C recommendations),
they provide a template and example on which
prospective studies can be designed.
One could argue that regional studies are some-
what provincial and limited in scope and that one
should be more concerned with national efforts.
However, the expense, need for funding, logistical
and communication concerns are formidable obsta-
cles. ACAS,6 the NASCET,8 and VA Cooperative
Studies30, 31 have amply demonstrated what cooper-
ative vascular surgeons can accomplish nationally,
but only with multimillion dollar budgets and mas-
sive organizational efforts.
SAVS has a strong tradition of participation and
high-quality clinical research from academic and
non-academic members. We are an academic society
but not a society of academic surgeons. It will be
important to build on this with the aid of the SAVS
leadership and the Committee on Research and
Resources. Pooling data in an organized fashion and
developing RCTs should become a priority of SAVS.
I look forward to this effort producing solid evi-
dence (Level I, Grade A) for the future practice of
vascular surgery.
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